PLSE on Nasdaq
PULSE BIOSCIENCES, INC.
American surgical and medical instruments and apparatus company. Summary from the record
Price unavailable
Last updated Oct 19, 2026.
Overview
Compare with Adagio Medical Holdings, Inc., QTREX Quantum Ltd. or Bluejay Diagnostics, Inc., or pick any stock.
- TickerPLSE on Nasdaq2
- IndustrySurgical & Medical Instruments & Apparatus2
- HeadquartersHayward, United States2
- Incorporated inDE3
- Business address3957 Point Eden Way, Hayward, Ca 945453
- Filer categoryNon-accelerated filer, Smaller reporting company3
- Legal formCorporation2
- LEI529900NJUBI06118FM732
- StatusActive2
- LEI statusLapsed (not renewed)2
- Registered addressc/o The Corporation Trust Company, Corporation Trust Center, 1209 Orange Street, 19801 Wilmington, United States2
- Registered withDivision of Corporations, Department of State, 69362772
See how the biggest companies compare on our leaderboards
We are a novel ablation company committed to health innovation using our patented Nano-pulse Stimulation (“NPS”) technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to nonthermally clear or kill targeted cells. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation (“nsPFA”) technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. We developed our proprietary nPulse System (formerly known as CellFX), a novel nsPFA delivery platform, and commercialized the initial application of its nsPFA technology to treat benign lesions of the skin. In parallel, we have designed a variety of applicators, or disposables, to explore the potential use of the nPulse platform to treat disorders in othe…4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue1¢$539.0K
- Research and development58¢$44.7M
- Selling, general and admin41¢$32.0M
Out of $350.0K in revenue.5 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Product revenue | $350.0K | $0 |
| Cost of product revenue | $539.0K | $0 |
| Research and development | $44.7M | $32.3M |
| Selling, general and administrative | $32.0M | $23.9M |
| Total cost and expenses | $77.3M | $56.3M |
| Loss from operations | -$76.9M | -$56.3M |
| Interest income | $4.2M | $2.7M |
| Other expense | -$52.0K | -$18.0K |
| Total other income | $4.2M | $2.7M |
| Net loss | -$72.8M | -$53.6M |
| Comprehensive loss | -$72.8M | -$53.6M |
| Net loss per share, basic and diluted (in dollars per share) | -$1.08 | -$0.92 |
| Weighted average common shares outstanding, basic and diluted (in shares) | 67.4M shares | 58.4M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $80.7M | $118.0M | |
| Accounts receivable | $274.0K | $0 | |
| Inventory | $136.0K | $0 | |
| Prepaid expenses and other current assets | $2.3M | $1.4M | |
| Total current assets | $83.4M | $119.4M | |
| Property and equipment, net | $1.1M | $1.2M | |
| Intangible assets, net | $575.0K | $1.2M | |
| Goodwill | $2.8M | $2.8M | |
| Right-of-use assets | $6.0M | $7.2M | |
| Other assets | $691.0K | $677.0K | |
| Total assets | $94.5M | $132.5M | |
| Accounts payable | $2.8M | $1.7M | |
| Accrued liabilities | $3.6M | $7.0M | |
| Lease liability, current | $1.6M | $1.4M | |
| Total current liabilities | $7.9M | $10.1M | |
| Lease liability, less current portion | $6.0M | $7.5M | |
| Total liabilities | $13.9M | $17.6M | |
| Preferred stock, $0.001 par value; authorized 50,000,000 shares; no shares issued and outstanding | $0 | $0 | |
| Common stock, $0.001 par value; authorized 500,000,000 shares; issued and outstanding 67,839,689 shares and 65,925,503 shares as of December 31, 2025 and 2024, respectively | $68.0K | $66.0K | |
| Additional paid-in capital | $543.9M | $505.3M | |
| Accumulated deficit | -$463.3M | -$390.5M | |
| Total stockholders equity | $80.7M | $114.9M | $44.4M |
| Total liabilities and stockholders equity | $94.5M | $132.5M | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 50.0M shares | 50.0M shares | |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 500.0M shares | 500.0M shares | |
| Common stock, shares issued (in shares) | 67.8M shares | 65.9M shares | |
| Common stock, shares outstanding (in shares) | 67.8M shares | 65.9M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $80.7M | $118.0M | |
| Accounts receivable | $274.0K | $0 | |
| Inventory | $136.0K | $0 | |
| Prepaid expenses and other current assets | $2.3M | $1.4M | |
| Total current assets | $83.4M | $119.4M | |
| Property and equipment, net | $1.1M | $1.2M | |
| Intangible assets, net | $575.0K | $1.2M | |
| Goodwill | $2.8M | $2.8M | |
| Right-of-use assets | $6.0M | $7.2M | |
| Other assets | $691.0K | $677.0K | |
| Total assets | $94.5M | $132.5M | |
| Accounts payable | $2.8M | $1.7M | |
| Accrued liabilities | $3.6M | $7.0M | |
| Lease liability, current | $1.6M | $1.4M | |
| Total current liabilities | $7.9M | $10.1M | |
| Lease liability, less current portion | $6.0M | $7.5M | |
| Total liabilities | $13.9M | $17.6M | |
| Preferred stock, $0.001 par value; authorized 50,000,000 shares; no shares issued and outstanding | $0 | $0 | |
| Common stock, $0.001 par value; authorized 500,000,000 shares; issued and outstanding 67,839,689 shares and 65,925,503 shares as of December 31, 2025 and 2024, respectively | $68.0K | $66.0K | |
| Additional paid-in capital | $543.9M | $505.3M | |
| Accumulated deficit | -$463.3M | -$390.5M | |
| Total stockholders equity | $80.7M | $114.9M | $44.4M |
| Total liabilities and stockholders equity | $94.5M | $132.5M | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 50.0M shares | 50.0M shares | |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 500.0M shares | 500.0M shares | |
| Common stock, shares issued (in shares) | 67.8M shares | 65.9M shares | |
| Common stock, shares outstanding (in shares) | 67.8M shares | 65.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$72.8M | -$53.6M |
| Depreciation | $406.0K | $512.0K |
| Amortization of intangible assets | $665.0K | $666.0K |
| Stock-based compensation | $21.5M | $13.6M |
| Non-cash lease expense | $1.2M | $923.0K |
| Loss on disposal of fixed assets | $0 | $6.0K |
| Accounts receivable | -$274.0K | $0 |
| Inventory | -$136.0K | $0 |
| Prepaid expenses and other current assets | -$912.0K | -$355.0K |
| Other non-current assets | -$14.0K | -$31.0K |
| Accounts payable | $1.1M | -$201.0K |
| Accrued liabilities | -$3.5M | $3.2M |
| Lease liabilities, net | -$1.4M | -$1.1M |
| Net cash used in operating activities | -$54.1M | -$36.3M |
| Purchases of property and equipment | -$315.0K | -$125.0K |
| Purchases of intangible assets | -$20.0K | $0 |
| Net cash used in investing activities | -$335.0K | -$125.0K |
| Proceeds from issuance of common stock under employee stock purchase plan | $586.0K | $478.0K |
| Proceeds from exercises of warrants, net of issuance costs | $14.1M | $49.4M |
| Proceeds from exercises of stock options | $2.5M | $871.0K |
| Proceeds from issuance of common stock and warrants in relation to rights offering, net of issuance costs | $0 | $59.6M |
| Payment of deferred issuance costs in relation to at-the-market equity offering program | $0 | -$281.0K |
| Net cash provided by financing activities | $17.2M | $110.1M |
| Net (decrease) increase in cash and cash equivalents | -$37.3M | $73.7M |
| Proceeds from exercise of warrants and stock options not yet received | $45.0K | $92.0K |
| Unpaid warrant issuance costs | $2.0K | $13.0K |
| Unpaid amounts related to purchase of equipment | $8.0K | $26.0K |
| Rights offering deemed pro-rata distribution to shareholders | $0 | $47.7M |
| Right-of-use asset obtained in exchange for lease liability | $0 | $830.0K |
No quarter-by-quarter statement was filed.
Leadership
Who has led PULSE BIOSCIENCES, INC., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
- Chief executive officerPaul A. Laviolette Jan 13, 2025 to now13
- Chief executive officerBurke Thomas Barrett May 22, 2024 to Jul 22, 202414
- Chief executive officerKevin Patrick Danahy Sep 27, 2022 to Nov 17, 202315
- Chief executive officerDarrin Uecker May 13, 2016 to Mar 24, 202116
- PresidentBurke Thomas Barrett May 22, 2024 to Jul 22, 202414
- PresidentDarrin Uecker May 13, 2016 to Mar 24, 202116
- Chief financial officerSandra Gardiner Nov 19, 2019 to Feb 28, 202217
- Chief financial officerBrian B. Dow May 13, 2016 to May 18, 201718
- Chief operating officerLiane Rae Teplitsky Aug 28, 2026 to now19
Board members and other officers (15)
- Chief Technology OfficerDarrin Uecker May 2, 2023 to now20
- Chief Commercial OfficeKevin Patrick Danahy Mar 22, 2022 to now21
- Chief Strategy OfficerMitchell E. Levinson Aug 20, 2021 to Sep 30, 202422
- EVP & GM, DermatologyEd Ebbers Jan 18, 2019 to Jun 3, 202123
- Board memberBurke Thomas Barrett May 22, 2024 to Jul 22, 202414
- Board memberPaul A. Laviolette Aug 13, 2024 to now24
- Board memberLaureen Debuono Oct 6, 2021 to Oct 6, 202125
- Board memberShelley D. Spray Nov 29, 2021 to Jun 6, 202326
- Board memberMaky Zanganeh Feb 13, 2017 to now27
- Board memberManmeet Singh Soni Nov 6, 2017 to now28
- Board memberRobert W. Duggan Nov 6, 2017 to now29
- Board memberThomas J. M. D. Fogarty Nov 6, 2017 to May 17, 201930
- Board memberDarrin Uecker May 13, 2016 to now16
- Board memberMitchell E. Levinson May 13, 2016 to May 9, 202331
- Board memberThierry B. Thaure May 13, 2016 to May 18, 201732
Former names
- Electroblate, Inc.Nov 13, 2014 to Nov 13, 20143
Timeline
Filings
325 filings to the SEC since October 2021: 7 annual reports, 15 quarterly reports, 106 major events, 120 insider forms, 7 large holders, 70 other. The latest 20:
- Oct 14, 20268-K EDGAR
- Oct 7, 20268-K EDGAR
- Sep 15, 20268-K EDGAR
- Sep 15, 2026424B5 EDGAR
- Sep 15, 20268-K EDGAR
- Sep 2, 20264 EDGAR
- Aug 28, 20264 EDGAR
- Aug 28, 20264 EDGAR
- Aug 28, 20263 EDGAR
- Aug 28, 20264 EDGAR
- Aug 28, 20263 EDGAR
- Aug 6, 20268-K EDGAR
- Aug 6, 2026424B5 EDGAR
- Aug 6, 202610-Q EDGAR
- Aug 6, 20268-K EDGAR
- Jul 29, 20268-K EDGAR
- Jun 15, 20264 EDGAR
- Jun 15, 20264 EDGAR
- Jun 15, 20264 EDGAR
- Jun 15, 20264 EDGAR
The 325 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
50 open-market trades by officers, directors and large owners since October 2021: 32 buys and 18 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | Teplitsky Liane RaeChief Operating Officer | Buy | 1,001 | $49.95 | $50.0K | Form 4 |
| Aug 31, 2026 | Teplitsky Liane RaeChief Operating Officer | Buy | 1,024 | $48.80 | $50.0K | Form 4 |
| Aug 28, 2026 | Teplitsky Liane RaeChief Operating Officer | Buy | 1,034 | $48.35 | $50.0K | Form 4 |
| Aug 26, 2026 | Teplitsky Liane RaeChief Operating Officer | Buy | 1,036 | $48.24 | $50.0K | Form 4 |
| May 11, 2026 | DUGGAN ROBERT WDirector | Buy | 660,233 | $19.69 | $13.0M | Form 4 |
| May 11, 2026 | LAVIOLETTE PAUL AChief Executive Officer | Buy | 15,000 | $19.69 | $295.4K | Form 4 |
| May 11, 2026 | LAVIOLETTE PAUL AChief Executive Officer | Buy | 15,000 | $19.69 | $295.4K | Form 4 |
| May 11, 2026 | DUGGAN ROBERT WDirector | Buy | 660,233 | $19.69 | $13.0M | Form 4 |
| Feb 18, 2026 | Danahy Kevin PatrickChief Commercial Officer | Sale | 5,000 | $23.64 | $118.2K | Form 4 |
| Feb 17, 2026 | Danahy Kevin PatrickChief Commercial Officer | Sale | 20,000 | $23.63 | $472.6K | Form 4 |
| Feb 13, 2026 | Danahy Kevin PatrickChief Commercial Officer | Sale | 20,000 | $23.53 | $470.6K | Form 4 |
| Feb 12, 2026 | Danahy Kevin PatrickChief Commercial Officer | Sale | 20,000 | $23.37 | $467.4K | Form 4 |
| Feb 11, 2026 | Danahy Kevin PatrickChief Commercial Officer | Sale | 20,000 | $25.20 | $504.0K | Form 4 |
| Feb 10, 2026 | Danahy Kevin PatrickChief Commercial Officer | Sale | 20,000 | $23.52 | $470.4K | Form 4 |
| Feb 9, 2026 | Danahy Kevin PatrickChief Commercial Officer | Sale | 20,000 | $21.45 | $429.0K | Form 4 |
| Oct 2, 2025 | Danahy Kevin PatrickChief Commercial Officer | Sale | 4,600 | $18.53 | $85.2K | Form 4 |
| Sep 19, 2025 | Danahy Kevin PatrickChief Commercial Officer | Sale | 400 | $18.48 | $7.4K | Form 4 |
| Sep 18, 2025 | Danahy Kevin PatrickChief Commercial Officer | Sale | 20,000 | $18.49 | $369.8K | Form 4 |
| Sep 17, 2025 | UECKER DARRINChief Technology Officer | Sale | 20,000 | $16.21 | $324.2K | Form 4 |
| Sep 16, 2025 | UECKER DARRINChief Technology Officer | Sale | 25,000 | $16.28 | $407.0K | Form 4 |
All 50 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Robert W. DugganSCHEDULE 13D/A, 7 filings Jun 13, 2022 to May 13, 202633
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23SEC EDGAREd Ebbers, EVP & GM, Dermatology
- 24SEC EDGARPaul A. Laviolette, Board member
- 25SEC EDGARLaureen Debuono, Board member
- 26SEC EDGARShelley D. Spray, Board member
- 27SEC EDGARMaky Zanganeh, Board member
- 28SEC EDGARManmeet Singh Soni, Board member
- 29SEC EDGARRobert W. Duggan, Board member
- 30
- 31SEC EDGARMitchell E. Levinson, Board member
- 32SEC EDGARThierry B. Thaure, Board member
- 33